Title of Invention

CARBOHYDRATE MIXTURES FOR DIETETIC FOOD PRODUCTS AND PHARMACEUTICALS

Abstract A carbohydrate mixture for dietetic foods and pharmaceuticals containing severai carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinai tract and enter the large intestine without being resorbed, that said carbohydrate component A is composed of at least one monosaccharide or of at ieast one oligosaccharide (disaccharide to hexasaccharide) or of a mixture of two or more of these saccharides, that the carbohydrate component B is composed of a polysaccharide (from heptasaccharide onwards) or of a mixture of two or more polysaccharides, that the carbohydrate component A = 5 to 95 wt-% and the carbohydrate component B = 5 to 95 wt-% of the sum of the carbohydrate components A + B (= 100 wt-%), and that at least 80 wt-% of the carbohydrates / saccharides of the carbohydrate components A and B have a prebiotic effect. The inventive carbohydrate mixture have not only a nutritive effect but they also stimulate health-promoting microorganisms present in the natural flora of the large intestine.
Full Text CARBOHYDRATE MIXTURES
DESCRIPTION
The invention relates to carbohydrate mixtures for dietetic foods and
pharmaceuticals, dietetic and pharmaceutical compositions containing said
carbohydrate mixtures, and to the use of said carbohydrate mixtures for
stimulating the human large intestinal flora.
As is generally known, carbohydrates represent one of the essential foundations
of nutrition. This is the reason why the most differing carbohydrates are admixed
to the most differing foods and also to pharmaceuticals. The task of the
carbohydrates therefore is primarily of the nutritive kind, and they serve as
roughage respectively.
Carbohydrates consist of monosaccharides, and are respectively composed
thereof. Depending on their polymerization degree, the carbohydrates are
indicated as oligosaccharides or polysaccharides or glycans respectively. (The
carbohydrates thereby are present as free oligosaccharides, as well as in a
bonded form such as for example in glycoproteins, proteoglycans and glycolipids.
Due to the variability of the monomers forming the carbohydrates, and due to the
position of the glycosidic bond and the anomeric state of the carbohydrates and
their conjugates, said carbohydrates and their conjugates represent an extremely
heterogeneous and extensive substance class.
Carbohydrates have most differing biological functions. Thus, they influence, for
example, the bacterial colonization of the large intestine, which is a prerequisite
for its normal function. The microflora of the large intestine takes part in the
intestinal functions in a very complex manner. This influence is preponderantly
exercised by the fermentation of food components, which have not been
resorbed in the small intestine. The fermentation encompasses a plurality of
functions such as the further digestion of these food components, the
detoxification of endogenously occurring metabolites, the synthesis of new
metabolites, some of them having a very specific effect, the return resorption of
bile acids, and many other processes. The normal microflora also has a health-
promoting effect in that it suppresses the growth of other pathogenous
microorganisms.
Bacteria, which produce lactic acid as their most important final metabolite (so-
called lactic acid-producing bacteria), play an essential role as the important
representatives of the normal microflora of the large intestine. Examples for this
group are bacteria of the lactobacillus and bifidobacterium genus. Therefore,
efforts have been undertaken for an extended period of time on ways to control
the development of a lactic acid-dominant intestinal flora by means of dietetic
measures. This is particularly important in cases when a normal intestinal flora is
not present or not sufficiently present due to processes caused by the
development such as, for example, of new born babies or due to pathogenous
states such as, for example, subsequent to an enteral antibiotic therapy or
another drug therapy or during and after enteral infections.
Carbohydrates are now increasingly used in food, "functional food" and
pharmaceuticals under the aspect of a biological efficiency. Thus, it is, for
example, known that some carbohydrates exercise a growth-promoting effect
upon various species of bifidobacteria, but also upon lactobacilli. Thus, galacto
oligosaccharides, for example, have a growth-promoting effect upon lactobacillus
casei. To date, however, only very specific species of carbohydrates having
determined properties are used for promoting certain biological actions.
Thus, WO 98/26787, for example, describes the use of ß-glucan and compounds
derived thereof for the promotion of the population of lactic acid-producing
microorganisms in the gastrointestinal tracts of human beings and animals.
Mixtures may also be used, which contain further prebiotic substances, the latter
not being specified in detail.
Moreover, mixtures are known from WO 96/13271 which contain various
oligosaccharides and polysaccharides apart from immunoglobulins. These
mixtures are used as a dietetic supplement, which, with oral administration, is
supposed to be active against various gastrointestinal pathogens. The
saccharides used are thereby indicated as soluble dietetic fibre, whereby it
concerns inulin, fructo-oligosaccharides, pectin, guar gum and mixtures thereof.
In EP 0 756 828 A1, fibre-containing nutrient compositions are described, which
contain in addition to oligosaccharides and/or starch, soluble polysacchararides
not representing starch and insoluble polysaccharides not representing starch.
It is the object of the present invention to provide improved carbohydrate
mixtures, which may be incorporated in dietetic nutritions and pharmaceuticals,
and which, in addition to their nutritive effect, also stimulate health-promoting
microorganisms present in the natural flora of the large intestine.
This object is solved by means of carbohydrate mixtures according to the
teaching of the present claims.
Thus, the carbohydrate mixtures according to the present invention, contain at
least two different, essentially soluble carbohydrate components A and B, which
remain undigested in the gastrointestinal tract and reaph the large intestine
unresorbed. The carbohydrate mixtures according to the present invention may
also consist exclusively of these two carbohydrate components A and B.
Carbohydrate component A thereby consists of at least one monosaccharide or
from at least one oligosaccharide. Oligosaccharides are thereby understood as
those comprising of 2 to 7 monosaccharide units. Hence, the oligosaccharides
refer to disaccharides, trisaccharides, tetrasaccharides, pentasaccharides and
hexaasaccharides. Carbohydrate component A may also be formed by a
compound of two or more of the mentioned saccharides. It may therefore be
comprised of only one monosaccharide or of a mixture of two or more
monosaccharides or of a mixture of one or more monosaccharide/s with one or
more oligosaccharide/s. It may also be comprised of any arbitrary number of
various monosaccharides and/or oligosaccharides of that kind.
Carbohydrate component B consists of at least one polvsaccharide comprising 7
or more monosaccharide units. Polysaccharides are understood as those starting
from heptasaccharide (e.g. heptasaccharide, oktasaccharide, nonasaccharide,
decasaccharid, etc.). Carbohydrate component B, may also be comprised of only
one polysaccharide of that kind or of any arbitrary number of polysaccharides of
that kind.
Accordingly, when in the following or in the claims, a carbohydrate component A
or B is mentioned, it may refer to any one of all of these variants.
Carbohydrate component A thereby represents up to 95 wt-% of the sum of
carbohydrate component A and carbohydrate component"B (A + B = 100 wt-%).
Carbohydrate component B fepresents 5 to 95 wt-% of the sum of carbohydrate
component A and carbohydrate component B.
At least 80 wt-% of the carbohydrates or saccharides out of the sum of
carbohydrate component A and B thereby have a prebiotic effect. Preferably, at
least 80 wt-% of the carbohydrates belonging to carbohydrate component A, and
also at least 80 wt-% of those belonging to carbohydrate component B, have a
prebiotic effect. In other words, preferably at least 80 wt-% each of the
carbohydrates or saccharides out of carbohydrate components A and B, are
intended to reach the large intestine in an undigested (hence not resorbable in
the small intestine) manner. In other words, these carbohydrates or saccharides
of carbohydrate components A and B in the gastrointestinal tract are neither
resorbed and digested in the stomach nor in the small intestine, but reach the
large intestine as such.
The proportion of the not prebioticaliy active carbohydrates or saccharides of
carbohydrate components A and B therewith amounts to a maximum of 20 wt-%.
These carbohydrates or saccharides refer to those, which are actually soluble,
but can be excreted in an undigested form. These carbohydrates can exercise a
physical effect in that they increase, for example, the volume of the faeces or
prompt a water adsorption.
Soluble carbohydrates in the sense of the present invention are understood as
those, which form a homogenous solution in the physical sense in water, in a
concentration of at least 1 g/l at room temperature (e.g. pursuant to Roempp's
Chemie Lexikon).
Such as it has already been stated, the inventive carbohydrate mixtures may
consist exclusively of the carbohydrate components A and B or may contain
them. For the assessment of the proportion determining the carbohydrate
components A and B in a dietary or pharmaceutical product, the following steps
are carried out:
In a first stage, all soluble carbohydrates are extracted from the product by
means of water. Fats and proteins are removed from the extract
In a second stage, the soluble carbohydrates, or the extract respectively, are
digested by means of human enzymes, e.g. human amylase, human pancreatic
juice or a small intestine ciliated border preparations. The thereby resulting non-
digested carbohydrates (except for the in-vivo-resorbable monosaccharides
obtained in this in-vitro experiment), constitute the two carbohydrate components
A and B, and 80 % thereof are supposed to be prebioticaliy active.
A prebiotically active carbohydrate according to the present invention is
understood as a carbohydrate, which reaches the large intestine undigested (and
hence is not resorbable in the small intestine), and there, it selectively
encourages the growth and/or the activity of one or of a restricted number of
bacterial species in the intestine, and consequently promotes health. This
prebiotic effect of such carbohydrates and their specific mechanisms are
described in detail in "G.R. Gibson & M.B. Roberfroid, J. Nutr. 1995; 125: 1401 -
1412", whereto explicit reference is herewith made, and the disclosure of which is
included in the present documents.
The inventive carbohydrate mixtures hence are those, wherein the
carbohydrates, which are soluble and undigested in the sense described above,
fulfil the herein specified criteria and constitute the carbohydrate components A
and B.
Apart from these carbohydrate components A and B, other carbohydrates may
be present as well. Amongst those are 1.) the actually soluble but digestible
carbohydrates, which are digestible according to the above-described second
stage, and 2.) the insoluble carbohydrates, which are resorbable./.digestible or
even not resorbable./.digestible.
These carbohydrates enumerated sub 1.) and 2.), may be present as such in any
arbitrary quantities in addition to the carbohydrate components A and B, in each
case depending on the desired final product. Preferably, the insoluble
carbohydrates constitute 0 to 10 wt-% of the carbohydrate mixtures.
Carbohydrate component A may, for example, consist of one or more of the
following carbohydrates: ß-galactooligosaccharides, a-galaetooligesaeeharides,
fructo-oligosaccharides, fuco-oligosaccharides, manno-oligosaccharides, xylo-
oligosaccharides, sialyl-oligosaccharides, N-glycoprotein oligosaccharides, O-
glycoprotein oligosaccharides, glycolipid oligosaccharides, cello-
oligosaccharides, chitosan-oligosaccharides, chitin-oligosaccharides,
galacturono-oligosaccharides, glucurono-oligosaccharides, ß-glucan
oligosaccharides, arabinoxylo-oligosaccharides, arabinogalacto-
oligosaccharides, xylogluco-oligosaccharides, galactomanno-oligosaccharides,
rhamno-oligosaccharides.
Carbohydrate component B may, for example, be formed of one or more of the
following carbohydrates or saccharides:
Soluble carbohydrates or saccharides: fruct(os)anes/inulins, galactans,
fucoidans, arabinans, xylans, xanthans, ß-glucans, galacturonans, N-glycans, O-
glycans, hyaluronic acids, chondroitins, xyloglucans, arabinogalactans, alginates,
carageenanes, galactomannans, arabinoxylanes, glycolipid glycans, glycoprotein
glycans, proteoglycans.
By means of a selective combination of oligosaccharides and polysaccharides,
and consequently the simultaneous presence of carbohydrate components A and
B, the health-promoting microorganisms in the large intestine may be promoted
by an essentially higher efficiency than it would be the case with only one of said
carbohydrate components. Thus, it is possible with the administration of the
inventive combination, to make very rapid restitution of a normal large intestinal
flora, to maintain same or to prophylactically prevent an alteration of the intestinal
flora during situations of stress, and thus to influence the bacterial colonization of
the large intestine in a way, which is more efficient than the one with the
previously used carbohydrates.
According to a preferred embodiment, at least 80 wt-% of carbohydrate
component A as well as of carbohydrate component B consist of carbohydrates,
which are bifidogenous and./.or which promote lactic acid bacteria. Due to such a
combination of oligosaccharides and polysaccharides having said properties, the
growth of the lactic acid bacteria may surprisingly be promoted in an essentially
stronger manner than this would be the case with oligosaccharides or
polysaccharides alone. Not only lactic acid bacteria are thereby promoted, which
are naturally present in the intestine, but also the growth of those is promoted -
optionally even in a selective manner - which are introduced exogenously.
Apart from this indirect action via the bacteria themselves and their metabolites
such as fatty acids (butyrate, propionate, etc.), pH effects and stimulation of
colonozytes, direct physical effects such as peristalsis, water content, quantity of
faeces, mechanical action upon the intestinal mucosa are likewise positively
influenced.
Thus, the inventive carbohydrate mixtures dispose not only of a nutritive effect
but also of a wide spectrum of activities. In addition to the above-described
biological effects, the following may also be achieved by means of the inventive
mixtures: stabilization of a natural microflora, prevention of pathogenous
substances./.organisms such as toxins, viruses, bacteria, fungi, transformed cells
and parasites from adhering, dissolution of complexes of toxins, viruses, bacteria,
fungi and other pathogens having endogenous cells, as well as their elimination
from the body, and an acceleration of wound healing.
Thus, the inventive mixtures are suitable for the prophylaxis and/or the treatment
of symptoms./.diseases occurring in conjunction with a disturbed intestinal flora,
for example, as a consequence of the association./.adhesion of the mentioned
substances and organisms with/on epithelia or other endogenous cells.
The carbohydrates or saccharides of carbohydrate components A and B primarily
differ in size. Nevertheless, mixtures have found to be particularly efficient,
wherein the carbohydrates or the saccharides of carbohydrate component A, on
the one hand, and of carbohydrate component B, on the other hand, are of a
different structure. This different structure may, for example, concern the
monosaccharide composition when, for example, fructans are used on the one
hand, and galactans, on the other hand. This different structure may likewise
concern the glycosidic bonding (e.g. a-galacto oligosaccharides versus ß-
galacto oligosaccharides or a-glucans (starch) versus ß-glucans (cellulose)).
The monomer composition, as well as the glycoside bonding may have an
influence on the chemical behaviour (e.g. solubility) or on the physiological
behaviour (e.g. digestibility).
The core of the inventive mixtures may inter alia be seen in that carbohydrates of
different sizes are used, which preferably and additionally belong to at least two
different "classes". With an administration of such mixtures, a synergetic effect
may occur relative to the prebiotic effects of the separate substance groups A
and B.
Thus, the carbohydrates of component A may not belong to one substance class
alone but may also be formed out of several classes (for example A: galacto-
oligosaccharides plus fuco-oligosaccharides), whereas the carbohydrates of
component B may equally originate from one substance class and also from
several substance classes (for example B: inulins plus xylans).
According to a further preferred embodiment, the carbohydrate component A
constitutes 95 to 60 wt-%, and in particular about 90 wt-%, and the carbohydrate
component B 5 to 40 wt-%, and in particular about 10 wt-% of the carbohydrates
present in toto.
Particularly efficient mixtures are those wherein at least 60 wt-%, and in particular
80 to 100 wt-% of the carbohydrates of carbohydrate component A belong to the
group of the galacto-oligosaccharides, and at least 60 wt-%, and in particular 80
to 100 wt-% of the carbohydrates of carbohydrate component B belong to the
group of the fructo-polysaccharides. Galacto-oligosaccharides are composed of
galactose residues of different glycosidic bonds, in particular at the ß 1-4 and ß 1-
6 position. At the reducing end, at p 1-4 of a glycosidic bond, glucose can be
present. Fructo-polysaecharides, fruetans, inuiins and levans being part thereof,
are composed of fructose residues of giycosidic bonds at the p 2-1 and p -6
position. At the reducing end, at p 2-1 of a glycosidic bond, glucose can be
present.
When a range is mentioned within the scope of the present invention, said range
indication wilt encompass and disclose at least all integral intermediate values,
and even all narrower ranges embraced by the wider range. This means that for
carbohydate component A as well as for carbohydrate component B, which may
both constitute 5 to 95 wt-%, that all intermediate values such as 6, 7, 8, 9... 13,
14... 25, 26, 27... 30, 31, 32, 33... 38, 39, 40, 41... 47, 48, 49, 50, 51... 59, 60, 61,
62, 63... 72, 73, 74... 79, 80, 81, 82... 87, 88, 89, 90, 91, 92, 93 and 94 wt-% are
likewise covered. The same applies to the indication that at least 80 wt-% of the
carbohydrates of carbohydrate component A and at least 80 wt-% of the
carbohydrates of carbohydrate component B are prebiotically active or promote
lactic acid bacteria and / or are bifidogenic. Thus, the term "at least 80 wt-%"
designates at least all single values between 80 wt-% and 100 wt-%, and hence,
for example, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,
99 and 100 wt-%. The carbohydrate components A and B may therewith
exclusively consist of such carbohydrates.
The mixing ratio between carbohydrate component A and carbohydrate
component B hence is 5 to 95 wt-%, or 95 to 5 wt-% respectively, and in
particular 95 to 60, or 5 to 40 wt-% respectively. Thus, at least all integral
narrower ranges are disclosed as well. The weight ratio between carbohydrate
component A and carbohydrate component B may therefore, for example, be
50:50, 51:49, 52:48, 53:47, 54:46, 55:45, 56:44, 57:43, 58:42, 49:41, 60:40,
61:39, 62:38, 63:37, 64:36, 65:35, 66:34, 67:33, 68:32, 69:31, 70:30, 71:29,
72:28, 73:27, 74:26, 75:25, 76:24, 77:23, 78:22, 79:21, 80:20, 81:19, 82:18,
83:17, 84:16, 85:15, 86:14, 87:13, 88:12, 89:11, 90:10, 91:9, 92:8, 93:7, 94:6,
and 95:5.
The molecular weight of the polysaccharides may thereby be of some MDas, and
may be extended to particular carbohydrates. Preferably, however,
polysaccharide molecules are used comprising up to 100 monosaccharide units.
For the production of the inventive carbohydrate mixtures, carbohydrates and
carbohydrate mixtures known to date und used in particular for the production of
foods or food products can be used. It is also possible to use raw materials
previously modified in a technical way. The preparation of the inventive mixtures
may thereby ensue by means of a simple blending of the correspondingly
selected carbohydrates or oligosaccharides with polysaccharides or the
carbohydrate mixtures. The initial components must thereby be so mixed with
one another that the inventive parameters are respected with the finished
inventive mixtures.
As raw materials may be used reserve carbohydrates (fructans, galacto-
oligosaccharides from legumes, fucoidan, a-glucane, laminarin, canragenan,
mannans, galactomannans, agar), natural gum, N-glycosidic bonded
carbohydrates of glycoproteins, O-glycosidic bonded carbohydrates of
glycoproteins, glycans of glycolipids, enzymaticly prepared carbohydrates
(galacto-oligosaccharides, gluco-oligosaccharides, xyio-oligosaccharides),
bacterial carbohydrates (such as xanthans), as well as oligosaccharides (galacto-
oligosaccharides, gluco-oligosaccharides (from a 1-2 and a 1-3 glucose
residues), xylo-oligosaccharides), as well as skeletal carbohydrates such as
celluloses, hemicelluloses (arabinans, galactans), pectins and chitins may be
used. The substances should preferably be of food-grade (cf. Complex
Carbohydrates in Foods, British Nutrition Foundation; Chapman & Hall, London
1990). It is also possible to carrying out an enzymatic modification of the raw
materials by means of hydrolases (e.g. glycosidases, transglycosidases and
lipases), transferases, isomerases (e.g. aldolases and ketolases),
oxidoreductases (e.g. oxidases) and reductases (e.g. glucosedehydrogenases),
lyases (e.g. polysaccharide lyases) and ligases of the raw materials and
products. Moreover, it is possible to carry out a technical modification of the raw
materials and products, namely by means of pressure (e.g. extrusion),
temperature (e.g. caramelization), organic syntheses, organic modification (e.g.
carboxymethylation and peracetylation), acid and/or alkaline hydrolysis and
fractionation (e.g. depending on size and/or physico-chemical parameters such
as charge and hydrophobicity).
The inventive carbohydrate mixtures thereby are essentially composed of the
hereinafter listed monosaccharides and of the thereof composed
oligosaccharides and polysaccharides. D-glucose, D-fructose, D-galactose, D-
mannose, L-fucose, D-N-acetylglucosamine, D-N-acetylgalactosamine, D-xylose,
L-rhamnose, D-arabinose, D-allose, D-talose, L-idose, D-ribose, as well as
monosaccharides comprising carboxyl groups such as D-galacturon acid, D-
glucuron acid, D-mannuron acid and/or the methylated forms thereof such as N-
acetylneuramin acid, N-glycolylneuramin acid and/or the Oacetyiated forms
thereof.
Moreover, these monomers and the thereupon based higher units can be
modified by means of -OSO3H groups and / or -OPO3H groups.
The subject matter of the present invention is also dietetic or pharmaceutical
compositions containing said inventive carbohydrate mixtures, and the use of
said above-described carbohydrate mixtures for promoting the flora of the large
intestine in humans. The term "promoting / promotion" represents a general term
for all of the above-listed biological actions. Thereto belongs in particular the
promotion of the growth of lactic acid-producing bacteria.
The inventive mixtures may be present in the following products:
Formulas for prematurely born babies, formulas for maturely born babies, infant
formulas, human milk fortifier, clinical nutrition (in general, the inventive mixture
may replace a part or the entirety of other components in these nutritions, such
as, for example, lactose, maltodextrin or starch, or may be added to the nutrition),
pharmaceuticals, dietetic supplement (as sachet in drinks).
In the following, carbohydrate mixtures representing various preferred
embodiments are described. The indications thereby refer to weight percent, if
not indicated otherwise. In these examples it is stated to which carbohydrate
components A or B the used carbohydrates belong. The carbohydrate
component A is thereby only called "A", and carbohydrate component B only "B".
Example 1
Composition
90 % A = galacto-oligosaccharides
transgalacto-oligosaccharides, e.g. Elixor® (Company Borculo, enzymatic from
lactose by means of ß-galactosidase)
10 % B = inulin
Inulin, e.g. Raftiline® HP (Company Orafti, extraction from chicories, physical
separation of the low-molecular oligosaccharides)
For the preparation of the transgaiacto-oiigosaccharides (Elixor®), lactose is
treated with ß-gaiactosidase. The lactose is thereby cataiyticafiy transformed in
galacto-oligosaccharides, whereby a piuraiity of gaiacto-oligosaccharides are
formed having varying chain lenghts. Primarily, disaccharides and trisaccharides
comprising 3 or 2 galactose units are thereby obtained.
Example 2
Composition
60 % A = galacto-oligosaccharides
transgalacto-oligosaccharides (enzymatic from iactose by means of ß-
galactosidase)
40 % B = inulin
inuiin, e.g. Raftiline® HP (Company Orafti, extraction from chicories, physical
separation of the low-molecular oligosaccharides)
Example 3
Composition
90 % A = gaiacturon acid oligosaccharides
enzymatic from pectin
10 % B = xylose polysaccharides
enzymatic from xyian (vegetable hemiceiiuiose)
Example 4
Composition
90 % A = fructo-oligosaccharides
enzymatic from inulin by means of endo-inuiinase
10 % B = cellulose polysaccharides
enzymatic from cellulose by means of cellulase
Example 5
Composition
90 % A = gaiacto-oligosaccharides
10 % B = arabinans
enzymatic from vegetable hemicellulose
Example 6
Composition
55 % A = gaiacto-oligosaccharides
45 % B = fructo-polysaccharides
Example 7
Composition
85 % A = galacturon acid oligosaccharides
15 % B = fructo-polysaccharides
Example 8
Composition
90 % A = giuco-oligosaccharides
enzymatic by means of giucosyitransferase
10 % B = fructo-polysaccharides
Example 9
Composition
90 % A = fuco-oligosaccharides
enzymatic from algae fucoidan
10 % B = fructo-polysaccharides
Example 10
Composition
90 % A = galacto-oligosaccharides
10 % B = fuco-polysaccharides
enzymatic from algae fucoidan
Example 11
Composition
55 % A = galacto-oligosaccharides
a-gaiacto-oligosaccharides from soya
45 % B = fucto-polysaccharides (inulin)
Example 12
Composition
80 % A = transgaiacto-oligosaccharaides
10 % A = galacturon acid oligosaccharides
10 % B = inulin
WE CLAIM :
1. Carbohydrate mixtures for dietetic food products and
pharamaceuticals whereby said carbohydrate mixtures contain
or consist of two different, substantially soluble carbohydrate
components A and B, which remain undigested in the
gastrointestinal tract and enter the large intestine without
being resorbed,
the carbohydrate component A is composed of at least one
monosaccharide or of at least one oligosaccharide having 2 to 6
monosaccharide units or of a mixture of two or of more of
these saccharides,
the carbohydrate component B is composed of a polysaccharide
having 7 or more monosaccharide units or of a mixture of two or
of more polysaccharides,
the carbohydrate component A = 5 to 95 weight percent and the
carbohydrate component B = 5 to 95 weight percent of the sum
of the carbohydrate components A + B (= 100 weight percent),
at least 80 weight percent of the carbohydrates/saccharides of
the carbohydrate components A and B have a prebiotic effect,
the carbohydrates/saccharides, which constitute the
carbohydrate compound A have a different structure than the
carbohydrates/saccharides, which constitute the carbohydrate
component B, and the carbohydrates/saccharides of the
carbohydrate component B are composed of a maximum of up to
100 monosaccharide units.
2. Carbohydrate mixtures according to claim 1, wherein at least
80 weight percent of the carbohydrates/saccharides of the
carbohydrate components A and B promote lactic acid bacteria
and/or are blfldogenic.
3. Carbohydrate mixtures according to one of claims 1 or 2,
wherein the weight percent of the carbohydrate component A
is higher than the weight percnet of the carbohydrate
component B.
4. Carbohydrate mixtures according to claim 3, wherein the
carbohydrate component A comprises 95 to 60 weight percent
and the carbohydrate component B comprises 5 to 40 weight
percent, with A + B = 100 weight percent
5. Carbohydrate mixtures according to claim 4, wherein the
carbohydrate component A comprises about 90 weight
percent and the carbohydrate component B comprises about
10 weight percent
6. Carbohydrate mixtures according to any one of the preceding
claims, wherein the carbohydates/saccharides of the
carbohydrate components A and B do not have any glucose
units linked at the a 1-4 and/or a 1-6 position.
7. Carbohydrate mixtures according to any one of the preceding
claims, wherein at least 60 weight percent and in particular 80
to 100 weight percent of the carbohydrates/saccharides of the
carbohydrate component A belong to the gatacto-
digosaccharlde group and at least 60 weight percent and in
particular 80 to 100 weight percent of the
carbohydrates/saccharides of the carbohydrate component B
belong to the fructo-polysaccharide group.
8. Carbohydrate mixtures according to any one of the preceding
claims, wherein apart from the carbohydrates/saccharides of
the carbohydrate components A and B, they contain an
insoluble carbohydrate or a soluble and digestible
carbohydrate or a mixture of one or more of these
carbohydrates.
9. A dietetical or pharmaceutical composition containing a
carbohydrate mixture according to any one of the preceding
claims.
10. Carbohydrate mixtures according to any one of the preceding
claims for promoting the flora of the large intestine in humans
and for promoting the growth of lactic acid bacteria.
A carbohydrate mixture for dietetic foods and pharmaceuticals containing severai
carbohydrates is provided according to the present invention. Said carbohydrate
mixture is characterized in that they contain or consist of two different,
substantially soluble carbohydrate components A and B, which remain
undigested in the gastrointestinai tract and enter the large intestine without being
resorbed,
that said carbohydrate component A is composed of at least one
monosaccharide or of at ieast one oligosaccharide (disaccharide to
hexasaccharide) or of a mixture of two or more of these saccharides,
that the carbohydrate component B is composed of a polysaccharide (from
heptasaccharide onwards) or of a mixture of two or more polysaccharides,
that the carbohydrate component A = 5 to 95 wt-% and the carbohydrate
component B = 5 to 95 wt-% of the sum of the carbohydrate components A + B
(= 100 wt-%), and that at least 80 wt-% of the carbohydrates / saccharides of the
carbohydrate components A and B have a prebiotic effect.
The inventive carbohydrate mixture have not only a nutritive effect but they also
stimulate health-promoting microorganisms present in the natural flora of the
large intestine.

Documents:

IN-PCT-2001-134-KOL-FORM-27.pdf

in-pct-2001-134-kol-granted-abstract.pdf

in-pct-2001-134-kol-granted-claims.pdf

in-pct-2001-134-kol-granted-correspondence.pdf

in-pct-2001-134-kol-granted-description (complete).pdf

in-pct-2001-134-kol-granted-examination report.pdf

in-pct-2001-134-kol-granted-form 1.pdf

in-pct-2001-134-kol-granted-form 18.pdf

in-pct-2001-134-kol-granted-form 2.pdf

in-pct-2001-134-kol-granted-form 26.pdf

in-pct-2001-134-kol-granted-form 3.pdf

in-pct-2001-134-kol-granted-form 5.pdf

in-pct-2001-134-kol-granted-priority document.pdf

in-pct-2001-134-kol-granted-reply to examination report.pdf

in-pct-2001-134-kol-granted-specification.pdf

in-pct-2001-134-kol-granted-translated copy of priority document.pdf


Patent Number 222746
Indian Patent Application Number IN/PCT/2001/134/KOL
PG Journal Number 34/2008
Publication Date 22-Aug-2008
Grant Date 21-Aug-2008
Date of Filing 02-Feb-2001
Name of Patentee N V NUTRICIA
Applicant Address EERSTE STATIONSSTRAAT 1886 NL-2712 HM ZIETERNEER
Inventors:
# Inventor's Name Inventor's Address
1 SAWATZKI, GUNTHER RICARDA-HUCH-STRASSE 13, D-35516 MUNZENBERG
2 STAHL, BERND PFINGSTWEIDSTRASSE 39, D-61381 FRIEDRICHSDORF
PCT International Classification Number A23L 1/00
PCT International Application Number PCT/EP99/05878
PCT International Filing date 1999-08-11
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 198 36 339.7 1998-08-11 Germany